The diverse mechanisms by which EZH2 inhibition may enhance treatment efficacy through overcoming chemoresistance, radioresistance, and improving immunotherapy response, suggest that EZH2 is a promising target for SCLC therapy. This evidence concerns the gene EZH2 and small cell lung carcinoma.